Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
AMCP 2026
Nashville, TN | April 13 - 16, 2026
Symbravo® | Migraine
Cost effectiveness of Symbravo® (MoSEICTM meloxicam and rizatriptan) compared with gepants for the acute treatment of migraine in adults in the United States
Symbravo® | Migraine
Dr. Ailani presents the "Cost effectiveness of Symbravo® (MoSEICTM meloxicam and rizatriptan) compared with gepants for the acute treatment of migraine in adults in the United States" poster
AXS-05 | Major Depressive Disorder
Real-world characteristics and treatment patterns of patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets, cariprazine, brexpiprazole, or esketamine
AXS-05 | Major Depressive Disorder
Dr. Syed presents the "Real-world characteristics and treatment patterns of patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets, cariprazine, brexpiprazole, or esketamine" poster
AXS-05 | Major Depressive Disorder
Real-world healthcare utilization and costs associated with using dextromethorphan-bupropion extended-release tablets versus branded comparators for the treatment of major depressive disorder
AXS-05 | Major Depressive Disorder
Dr. Leslie Citrome presents the "Real-world healthcare utilization and costs associated with using dextromethorphan-bupropion extended-release tablets versus branded comparators for the treatment of major depressive disorder" poster
AXS-05 | Major Depressive Disorder
Healthcare costs for patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets as a first or subsequent line of treatment
AXS-05 | Major Depressive Disorder
Dr. Leslie Citrome presents the "Healthcare costs for patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets as a first or subsequent line of treatment" poster
AXS-05 | Major Depressive Disorder
Anxiolytic effects of dextromethorphan-bupropion (45mg/105mg): Post hoc analyses across trials in major depressive disorder
AXS-12 | Narcolepsy
AXS-12 for the treatment of narcolepsy: Topline results from the phase 3 SYMPHONY trial
Sunosi® | Excessive Daytime Sleepiness
Real-world use of solriamfetol for excessive daytime sleepiness in patients with obstructive sleep apnea in the US
